A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia
Michael Murphy,
Anthony Dowling,
Christopher Thien,
Emma Priest,
Donna Morgan Murray,
Santosh Kesari
Affiliations
Michael Murphy
1Department of Neurosurgery, St Vincent's Hospital, Fitzroy, Australia
Anthony Dowling
3Department of Oncology, St Vincent's Hospital, Fitzroy, Australia
Christopher Thien
1Department of Neurosurgery, St Vincent's Hospital, Fitzroy, Australia
Emma Priest
1Department of Neurosurgery, St Vincent's Hospital, Fitzroy, Australia
Donna Morgan Murray
5Nativis, Inc., Department of Clinical and Regulatory Affairs, Seattle, WA 98109, USA
Santosh Kesari
6John Wayne Cancer Institute & Pacific Neuroscience Institute, Department of Translational Neurooncology and Neurotherapeutics, Santa Monica, CA, 90404, USA
Aim: Evaluation of the Nativis Voyager®, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). Materials & methods: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2–4 months. Results: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams. Conclusion: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.
